Strain Data Sheet

RBRC02414

Strain Information

Image
BRC No.RBRC02414
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameA/J.Cg-Nfe2l2<tm1Mym>
Former Common nameNrf2 knock out mouse (A/J background)
H-2 Haplotype
ES Cell lineE14 [129P2/OlaHsd]
Background strainA
Appearancealbino [a/a b/b c/c]
Strain developmentDeveloped by Masayuki Yamamoto, Institute of Basic Medical Sciences and Center for Tsukuba Advanced Research Alliance, University of Tsukuba in 1996. The targeting vector containing lacZ-neo cassette was transferred into E14 ES cells to replace the 1.2 kb segment containing the rest of the exon 5 coding sequence of the Nrf2 gene.
Strain descriptionNrf2 (Nfe2l2) Knockout mice. This strain is a useful model for the in vivo analysis of chemical carcinogenesis and resistance to anti-cancer drugs. A phenolic antioxidant significantly induced the expression of phase II enzymes such as glutathione S-transferase and NAD(P)H: quinone oxidoreductase in normal mice. However, in the homozygous Nrf2 deficient mice the induction of the phase II enzymes by a phenolic antioxidant was largely eliminated in the liver and intestine. Since Nrf2 is constantly degraded by proteasome under normal condition, it is hardly to detect Nrf2 protein in the absence of stimuli. Electrophilic chemicals, such as DEM (diethyl maleate) and tBHQ (tert-buthyl hydroquinone), are generally used to stabilize Nrf2. Or proteasomal inhibitors, such as MG132, are also effective increasing the protein amount of Nrf2. C57BL/6 background (RBRC01390), BALB/c background (RBRC02190), A/J background (RBRC02414), ICR mixed background (RBRC00984). Homozygous mutant mice are viable and fertile, but show lower reproductive performance.
Colony maintenanceHomozygote x Heterozygote [or Crossing to A/JJmsSlc]
References
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.
Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y
Biochem. Biophys. Res. Commun., 236, 313-322 (1997). 9240432

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Nfe2l2nuclear factor, erythroid derived 2, like 22Nfe2l2targeted mutation 1, Masayuki Yamamoto
  • immunodeficiency, developmental delay, and hypohomocysteinemia(MedGEN)
    • lacZbeta-galactosidase (E. coli)2
  • immunodeficiency, developmental delay, and hypohomocysteinemia(MedGEN)
    • neoneomycin resistance gene (E. coli)2herpes simplex virus thymidine kinase promoter (HSV tk promoter)
  • immunodeficiency, developmental delay, and hypohomocysteinemia(MedGEN)
    • nlsSV40 large T antigen nuclear localization signal (NLS)2nls
  • immunodeficiency, developmental delay, and hypohomocysteinemia(MedGEN)

    • Phenotype

    Annotation by Mammalian phenotyhpe ontology
  • abnormal behavior(MP:0004924)

  • abnormal enamel morphology(MP:0002576)

  • abnormal glomerular capillary morphology(MP:0011320)

  • abnormal glomerular mesangium morphology(MP:0011339)

  • abnormal incisor color(MP:0010096)
    • more 52 phenotypes
  • abnormal iron homeostasis(MP:0005637)

  • abnormal iron level(MP:0001770)

  • abnormal leukocyte adhesion(MP:0003628)

  • abnormal macrophage physiology(MP:0002451)

  • abnormal physiological response to xenobiotic(MP:0008872)

  • abnormal renal glomerulus morphology(MP:0005325)

  • abnormal respiratory system physiology(MP:0002133)

  • abnormal tooth morphology(MP:0002100)

  • ameloblast degeneration(MP:0000129)

  • cachexia(MP:0005150)

  • circling(MP:0001394)

  • decreased CD4-positive, alpha-beta T cell number(MP:0008075)

  • decreased T cell number(MP:0005018)

  • decreased body weight(MP:0001262)

  • decreased creatinine clearance(MP:0005558)

  • decreased urine creatinine level(MP:0011471)

  • enlarged lymph nodes(MP:0000702)

  • glomerular crescent(MP:0011506)

  • glomerulonephritis(MP:0002743)

  • glomerulosclerosis(MP:0005264)

  • hematopoietic system phenotype(MP:0005397)

  • hepatic steatosis(MP:0002628)

  • homeostasis/metabolism phenotype(MP:0005376)

  • hypoglycemia(MP:0000189)

  • increased IgG level(MP:0002493)

  • increased IgM level(MP:0002494)

  • increased acute inflammation(MP:0005088)

  • increased anti-double stranded DNA antibody level(MP:0004762)

  • increased anti-nuclear antigen antibody level(MP:0004794)

  • increased cerebral infarct size(MP:0006060)

  • increased circulating alanine transaminase level(MP:0002941)

  • increased circulating interleukin-6 level(MP:0008596)

  • increased circulating tumor necrosis factor level(MP:0008553)

  • increased hepatocyte apoptosis(MP:0003887)

  • increased incidence of tumors by chemical induction(MP:0004499)

  • increased kidney cell proliferation(MP:0011440)

  • increased liver iron level(MP:0008807)

  • increased lung weight(MP:0005630)

  • increased mesangial cell number(MP:0011427)

  • increased spleen weight(MP:0004952)

  • increased stomach tumor incidence(MP:0010301)

  • increased susceptibility to experimental autoimmune uveoretinitis(MP:0004821)

  • increased susceptibility to induced colitis(MP:0008537)

  • increased susceptibility to ischemic brain injury(MP:0003076)

  • increased susceptibility to xenobiotic induced morbidity/mortality(MP:0009766)

  • increased urine protein level(MP:0002962)

  • liver inflammation(MP:0001860)

  • lung inflammation(MP:0001861)

  • oxidative stress(MP:0003674)

  • premature death(MP:0002083)

  • pulmonary fibrosis(MP:0006050)

  • weight loss(MP:0001263)
    • Detailed phenotype data

    Ordering Information

    Donor DNASimian virus 40 Large T antigen nuclear localization signal (NLS), E. coli lacZ, herpes simplex virus thymidine kinase promoter (HSV tk promoter), E. coli neo, mouse Nrf2 genomic DNA
    Research applicationCancer Research
    Cell Biology Research
    Metabolism Research
    Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Biochem. Biophys. Res. Commun., 236, 313-322 (1997).In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. After deposition of the BIOLOGICAL RESOURCE, two years are assumed to be a collaborative research with the DEPOSITOR. The DEPOSITOR maintains the patent and the intellectual property right of the BIOLOGICAL RESOURCE. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE.
    DepositorMasayuki Yamamoto (University of Tsukuba)
    Strain Statusan icon for Frozen embryosFrozen embryos
    Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
    Cryopreserved embryos (within 1 month)
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    4. Acceptance of responsibility for living modified organism (Japanese / English)
    Lab HP (Japanese)
    Genotyping protocol -PCR-
    Mouse of the Month Apr 2012

    BRC mice in Publications

    No Data